These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

125 related articles for article (PubMed ID: 3919191)

  • 1. Pro-UK: another entry in the thrombolytic arena.
    Goldsmith MF
    JAMA; 1985 Mar 22-29; 253(12):1694-5. PubMed ID: 3919191
    [No Abstract]   [Full Text] [Related]  

  • 2. Usefulness of intravenous thrombolytic therapy with pro-urokinase in acute myocardial infarction.
    Bode C; Schuler G; Schwarz F; Zimmermann R; Horn A; Kuebler W
    Am J Cardiol; 1987 Aug; 60(4):371. PubMed ID: 3113225
    [No Abstract]   [Full Text] [Related]  

  • 3. [Thrombolytic therapy in acute myocardial infarct].
    Bode C; Baumann H; von Hodenberg E; Kübler W
    Med Klin (Munich); 1992 Feb; 87(2):64-9. PubMed ID: 1542285
    [No Abstract]   [Full Text] [Related]  

  • 4. Clot-selective coronary thrombolysis with pro-urokinase.
    Loscalzo J; Wharton TP; Kirshenbaum JM; Levine HJ; Flaherty JT; Topol EJ; Ramaswamy K; Kosowsky BD; Salem DN; Ganz P
    Circulation; 1989 Apr; 79(4):776-82. PubMed ID: 2494004
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Tissue-type plasminogen activator and pro-urokinase--new fibrinolytic agents in the treatment of myocardial infarction].
    Czyrski J
    Wiad Lek; 1989 Apr; 42(7):450-2. PubMed ID: 2516932
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Intravenous thrombolytic therapy with a combination of single-chain urokinase-type plasminogen activator and recombinant tissue-type plasminogen activator in acute myocardial infarction.
    Bode C; Schuler G; Nordt T; Schönermark S; Baumann H; Richardt G; Dietz R; Gurewich V; Kübler W
    Circulation; 1990 Mar; 81(3):907-13. PubMed ID: 2106403
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Potentiation of the thrombolytic efficacy of single-chain urokinase (Pro-urokinase) by heparin.
    Gulba DC; Fischer K; Reil GH; Daniel WG; Lichtlen PR
    Thromb Haemost; 1988 Oct; 60(2):350-1. PubMed ID: 3146150
    [No Abstract]   [Full Text] [Related]  

  • 8. Randomized, double-blinded multicenter study. Comparison of intracoronary single-chain urokinase-type plasminogen activator, pro-urokinase (GE-0943), and intracoronary urokinase in patients with acute myocardial infarction.
    Kambara H; Kawai C; Kajiwara N; Niitani H; Sasayama S; Kanmatsuse K; Kodama K; Sato H; Nobuyoshi M; Nakashima M
    Circulation; 1988 Oct; 78(4):899-905. PubMed ID: 3139325
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Acyl enzymes and pro-urokinase: promising new thrombolytic agents].
    Samama M; Horellou MH; Nguyen G; Conard J
    Haemostasis; 1986; 16 Suppl 4():35-9. PubMed ID: 3095199
    [No Abstract]   [Full Text] [Related]  

  • 10. Tissue-type plasminogen activator (t-PA) and single chain urokinase-type plasminogen activator (scu-PA): potential for fibrin-specific thrombolytic therapy.
    Collen D
    Prog Hemost Thromb; 1986; 8():1-18. PubMed ID: 3104986
    [No Abstract]   [Full Text] [Related]  

  • 11. Increased thrombin levels during thrombolytic therapy in acute myocardial infarction. Relevance for the success of therapy.
    Gulba DC; Barthels M; Westhoff-Bleck M; Jost S; Rafflenbeul W; Daniel WG; Hecker H; Lichtlen PR
    Circulation; 1991 Mar; 83(3):937-44. PubMed ID: 1900225
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [New thrombolytic agents in myocardial infarction].
    Charbonnier B; Lang M; Brochier M
    Arch Mal Coeur Vaiss; 1987 Nov; 80(12):1785-91. PubMed ID: 3128222
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Thrombolytic and pharmacokinetic properties of a conjugate of recombinant single-chain urokinase-type plasminogen activator with a monoclonal antibody specific for cross-linked fibrin in a baboon venous thrombosis model.
    Collen D; Dewerchin M; Rapold HJ; Lijnen HR; Stassen JM
    Circulation; 1990 Nov; 82(5):1744-53. PubMed ID: 2121385
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Hyperacute stroke therapy with tissue plasminogen activator.
    Alberts MJ
    Am J Cardiol; 1997 Aug; 80(4C):29D-34D; discussion 35D-39D. PubMed ID: 9284041
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Biological and thrombolytic properties of proenzyme and active forms of human urokinase--III. Thrombolytic properties of natural and recombinant urokinase in rabbits with experimental jugular vein thrombosis.
    Collen D; Stassen JM; Blaber M; Winkler M; Verstraete M
    Thromb Haemost; 1984 Aug; 52(1):27-30. PubMed ID: 6541817
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Single-chain urokinase-type plasminogen activator: mechanism of action and thrombolytic properties.
    Lijnen HR; Stump DC; Collen DC
    Semin Thromb Hemost; 1987 Apr; 13(2):152-9. PubMed ID: 3114883
    [No Abstract]   [Full Text] [Related]  

  • 17. Thrombolytic therapy in renal vein thrombosis.
    Harrington JT
    Arch Intern Med; 1984 Jan; 144(1):33-4. PubMed ID: 6691770
    [No Abstract]   [Full Text] [Related]  

  • 18. [A double-blind comparative study of intracoronary administration of GE-0943 and urokinase: multicenter study].
    Kambara H; Kawai C; Kajiwara N; Kammatsuse K; Nitani H; Sasayama S; Kodama K; Sato H; Nobuyoshi M; Nakashima M
    Kokyu To Junkan; 1989 Jul; 37(7):749-56. PubMed ID: 2678331
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Plasminogen activators as thrombolytic agents in myocardial infarction].
    Chamone DA; Massumoto C; Fujimura AY; Pileggi F; Bellotti G
    Rev Hosp Clin Fac Med Sao Paulo; 1989; 44(6):288-94. PubMed ID: 2518605
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Fibrin binding and zymogenic properties of single-chain urokinase (pro-urokinase).
    Gurewich V; Pannell R
    Semin Thromb Hemost; 1987 Apr; 13(2):146-51. PubMed ID: 3114882
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 7.